A clinical trial has backed the safety and efficacy of one of Novo Nordisk's weight-loss medicines in children as young as six, showing a significant drop in body mass index (BMI).
It's possible that Alzheimer's disease could be added to the lengthening list of health conditions that can be improved by treatment with GLP-1 receptor agonists.
The European Medicines Agency (EMA) has started a review of two Novo Nordisk drugs used to treat obesity and those overweight, following reports of suicidal thoughts or se
Eli Lilly has decided to wait for the readout of the second of its two phase 3 trials for tirzepatide in obesity, rather than filing on the strength of its first, positive study.